15 citations
,
May 1987 in “Fundamental and applied toxicology” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
March 2023 in “Oxford University Press eBooks” 11 citations
,
April 2014 in “Journal of Clinical Virology” Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.
April 2010 in “Nature Reviews Urology”
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
January 2021 in “Universal Journal of Pharmaceutical Research” Russelia equisetiformis extract protects against liver damage from paracetamol.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
1 citations
,
February 2020 in “Journal of the Canadian Association of Gastroenterology” An 8-year-old boy developed a rare condition after a liver transplant, which improved after changing his medication.
14 citations
,
October 1977 in “The Lancet” 3 citations
,
January 2019 in “Research journal of pharmacy and technology” The hair tonic with menthol grew longer hair, but both formulas had similar overall hair growth.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
8 citations
,
January 2011 in “Organic and Biomolecular Chemistry” Minoxidil reacts to nitrosation 7 times more than phenol, mainly due to its -NH₂ groups, leading to the creation of N-nitrosominoxidil.
March 2021 in “Research Square (Research Square)” Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
76 citations
,
January 1998 in “Mammalian Genome” 3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
7 citations
,
January 1993 in “Rheumatology” Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.
4 citations
,
June 2020 in “BMC Ophthalmology” Minoxidil can cause a rare eye condition, but it was successfully treated with oral Eplerenone in one case.
98 citations
,
April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively blocks rat enzymes, but with varying methods and strength.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.